



► PHARMA POOL

Joseph Devaney
**ASTELLAS NAMES VP, GOVERNMENT
AFFAIRS AND POLICY**



Astellas has appointed Joseph Devaney as VP, government affairs and policy, Americas. Based in Astellas' Washington, D.C., office, Mr. Devaney is responsible for leading Astellas' government Affairs and Policy team and developing, communicating, and implementing the company's federal and state government strategies, engagement activities, and policy development across all functional areas. He also serves as a key representative of Astellas to policy decision leaders and trade organizations.

Mr. Devaney joins Astellas after 20 years at Sanofi and its predecessor companies, where he held roles of increasing responsibility in public policy and market access, including most recently the role of VP of federal and state relations.

► BIOPHARMA POOL

Greg Doyle
LEADING BIOSCIENCES APPOINTS CEO



Leading BioSciences, a clinical-stage biopharmaceutical company advancing programs that address medical conditions resulting from a breakdown of the mucosal barrier, has appointed Greg Doyle as CEO. Mr. Doyle, a long-standing member of the executive management team and board of directors, served as chief operations officer and chief financial officer.

Dr. Glenn Nedwin
**SECOND GENOME APPOINTS
CEO AND PRESIDENT**



Second Genome, a privately held biopharmaceutical company developing novel medicines through innovative microbiome science, has appointed Glenn Nedwin, Ph.D., as CEO and president. Dr. Nedwin joins the company as it accelerates the translation of its microbiome discoveries into a pipeline of clinical opportunities.

Mike Sherman
ENDOCYTE APPOINTS PRESIDENT AND CEO
Endocyte, a leading developer of targeted small



molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, has appointed Mike Sherman president and CEO. Mr. Sherman has served as Endocyte's chief financial officer since 2006 and undertook the additional role of chief operating officer in 2014.

► BIOTECH POOL

Dr. Burkhard Blank
ACORDA APPOINTS CHIEF MEDICAL OFFICER



Acorda Therapeutics has named Burkhard Blank, M.D., chief medical officer. Dr. Blank was appointed as Acorda's interim CMO in January 2016, and previously served as CMO for several biopharmaceutical companies, including Boehringer Ingelheim.

Dr. Blank's primary responsibilities include: setting strategy for and execution of development programs from clinical trials through regulatory filings; oversight of postmarketing studies for approved products; and management of the company's medical affairs, clinical operations, regulatory affairs, drug safety, and biostatistics departments.

Dr. Paul McKenzie
**BIOGEN NAMES EXECUTIVE VP,
PHARMACEUTICAL OPERATIONS &
TECHNOLOGY**



Biogen has promoted Paul McKenzie, Ph.D., to executive VP, pharmaceutical operations and technology, from his previous position as senior VP of global biologics manufacturing and technical operations.

Dr. McKenzie is leading the organization responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering. He will also oversee construction and operation of Biogen's advanced biologics manufacturing facility in Solothurn, Switzerland.

► SPECIALTY PHARMA

Steven Holtzman
DECIBEL THERAPEUTICS APPOINTS TOP EXEC
Decibel Therapeutics, a hearing company focused



on discovering and developing new therapies to protect, repair, and restore hearing, has named industry veteran Steven Holtzman to president and chief executive officer.

Mr. Holtzman succeeds interim CEO Kevin Starr, a partner at Third Rock Ventures, who remains chairman of the board of directors.

Mr. Holtzman joins the company from Biogen, Inc., where he most recently served as executive VP, corporate development.

Louis Vollmer
**IROKO PHARMACEUTICALS APPOINTS
PRESIDENT AND CEO**



Iroko Pharmaceuticals has named Louis Vollmer president and CEO; he had been serving as president since March 2015. He succeeds Osagie Imasogie, Iroko's founder, as CEO; Mr. Imasogie remains Iroko's chairman. Mr.

Vollmer is charged with overseeing the day-to-day operations and long-term strategic planning of Iroko, focusing on maximizing the potential of the company's SoluMatrix franchise brands, expanding the company's global presence, and creating and acquiring innovative treatment options for responsible pain management.

► CONSULTING POOL

Dr. Thomas Bramley
XCENDA NAMES NEW PRESIDENT



Leading the way in providing additional client services is Xcenda's new President Thomas Bramley, Ph.D. Dr. Bramley has helped grow the organization from a health economics and outcomes research firm to a global leader in commercialization support. With more than 15 years of experience advising leadership teams in the pharmaceutical industry on real-world evidence generation and market access principles to optimize product success in value-based markets, he is leading Xcenda's efforts to help manufacturers demonstrate the value of their pharmaceutical products while improving patient access to medications. ^{PV}

FOR BONUS CONTENT
USE YOUR QR CODE READER
OR GO TO
bit.ly/PV0916-Pool



(c) PharmaLinx LLC. Rights do not include promotional use. For distribution or printing rights, contact mwals@pharmavoices.com

► BIOPHARMA POOL

Dr. Arthur Bertolino
CELLCEUTIX NAMES PRESIDENT AND CHIEF MEDICAL OFFICER

Cellceutix, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, has appointed Arthur Bertolino, M.D., Ph.D., president and chief medical officer.

During his career, Dr. Bertolino has held several key positions, including VP of dermatology and VP and global head of translational medicine for dermatology, Novartis Institutes for Biomedical Research (NIBR).

Dr. Jason Coloma
CORVUS PHARMACEUTICALS CREATES NEW POST OF CHIEF BUSINESS OFFICER

Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, has named Jason Coloma, Ph.D., to the newly created post of senior VP and chief business officer.

Most recently, he was global head of Roche oncology business development.

Dr. Jean-Marie Cuillerot
AGENUS APPOINTS VP AND GLOBAL HEAD OF CLINICAL DEVELOPMENT

Agenus, an immuno-oncology company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, has appointed Jean-Marie Cuillerot, M.D., as VP and global head of clinical development.

Dr. Cuillerot joins the company with 16 years of experience in oncology clinical research and drug development. Most recently, he served as the global head of clinical development, immuno-oncology, and VP of clinical immunotherapy/immuno-oncology at EMD Serono Research and Development Institute, an affiliate of Merck Serono.

Douglas Jermasek
KERYX BIOPHARMACEUTICALS NAMES VP, MARKETING AND STRATEGY

Keryx Biopharmaceuticals, a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, welcomes Douglas Jermasek as VP, marketing and strategy. In this role, he is responsible for brand strategy, product positioning, marketing, market access, and patient services for the company's lead medicine, Auryxia (ferric citrate).

Before joining Keryx, from 2002 to 2014, he had commercial roles of increasing responsibility within Genzyme/Sanofi's global renal business, culminating in 2012 when he was appointed to

the role of senior VP and general manager of that business.

Jonas Niaura
AVIRAGEN THERAPEUTICS APPOINTS VP, CORPORATE DEVELOPMENT AND STRATEGY

Aviragen Therapeutics, a pharmaceutical company that is developing the next generation of antivirals, has appointed Jonas Niaura as VP, corporate development and strategy.

Before joining Aviragen, Mr. Niaura was head of search and evaluation for infection, neuroscience, and GI, at AstraZeneca.

Dr. Lisa Nolan
REXAHN PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM

Rexahn Pharmaceuticals, a clinical-stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, has appointed Lisa Nolan, Ph.D., to the newly created position of chief business officer. Dr. Nolan, who held similar positions at Relmada Therapeutics, Topigen Pharmaceuticals, and SkyePharma, brings more than two decades of experience in corporate strategy, M&A, funding partnerships, and out-licensing, and in-licensing of development-stage clinical assets.

Dr. Stuart Silverman
KALYTERA THERAPEUTICS APPOINTS SENIOR VP, MEDICAL AFFAIRS

Kalytera Therapeutics, a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has appointed Stuart Silverman, M.D., senior VP, medical affairs.

Dr. Silverman is also a clinical professor of medicine at the University of California, Los Angeles, David Geffen School of Medicine.

Dr. Timothy Whitaker
ALDER BIOPHARMACEUTICALS APPOINTS CHIEF MEDICAL OFFICER

Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, has appointed Timothy Whitaker, M.D., as chief medical officer. Dr. Whitaker is charged with providing strategic oversight of Alder's clinical development pipeline and for clinical operations and medical and regulatory affairs. He plays a fundamental role in the clinical development of ALD403 for migraine prevention as it advances through pivotal trials and toward a planned biologic license application (BLA) with the FDA.

He joins Alder from Shire, where he has held clinical development positions of increasing responsibility since 2004, most recently as the VP and neuroscience therapeutic area head of global clinical development.

► BIOTECH POOL

Ranya Dajani
ADVAXIS APPOINTS VP, CORPORATE DEVELOPMENT

Advaxis, a clinical-stage biotechnology company developing cancer immunotherapies, has named Ranya Dajani VP, corporate development. Ms. Dajani joins the company from Bristol-Myers Squibb, where she worked for almost 20 years in business development and finance.

Joseph Johnston
CATABASIS PHARMACEUTICALS NAMES VP, REGULATORY AFFAIRS

Catabasis Pharmaceuticals, a clinical-stage biopharmaceutical company, has named Joseph Johnston VP, regulatory affairs. Mr. Johnston brings to Catabasis more than 25 years of pharmaceutical industry experience, most recently serving as VP, regulatory affairs and quality, at Ionis Pharmaceuticals.

Dr. Andrew Mulberg
AMICUS THERAPEUTICS APPOINTS VP, REGULATORY STRATEGY

Amicus Therapeutics, a global biotechnology company at the forefront of rare and orphan diseases, has appointed Andrew Mulberg, M.D., as VP, regulatory strategy. He is responsible for directing global regulatory strategies for all Amicus programs to bring multiple therapies to patients with rare and devastating diseases. Dr. Mulberg is a pediatric gastroenterologist who has spent the past six years working at the U.S. Food and Drug Administration, most recently as deputy director of the division of gastroenterology and inborn errors products.

► SPECIALTY POOL

Mark Fraga
Dr. Scott Kelley
Dan Thornton
FLEXION THERAPEUTICS ADDS THREE NEW EXECUTIVES

Flexion Therapeutics has named three new executives in key marketing, medical affairs, and market access roles. Mark Fraga, Scott Kelley, M.D., and Dan Thornton take on VP positions at Flexion as the company prepares to submit a new drug application (NDA) for its drug candidate Zilretta, a potential treatment for patients with moderate to severe knee osteoarthritis (OA) pain.

Mr. Fraga, VP, marketing, is a proven global marketing and commercialization leader in the pharmaceutical and medical device markets. Before joining Flexion, Mr. Fraga served as head of global marketing at Sanofi, where he led two franchises

in OA and surgical devices, including Synvisc, an injectable product for OA of the knee.

Dr. Kelley, VP, medical affairs, has more than 25 years of clinical, academic, and industry medical affairs experience. Most recently, he served as VP, global medical affairs, at Sanofi where he oversaw global data generation, data dissemination, and key opinion leader engagement for the biosurgery portfolio including Synvisc.

Mr. Thornton, VP, market access, has had leadership roles for almost 20 years in patient and market access, pricing and distribution, and market development for a number of biotechnology and pharmaceutical firms. Most recently, he was VP of market access and patient services at Chiasma, where he built a comprehensive patient services and market access organization for the launch of an oral product for the treatment of acromegaly.

▶ DIAGNOSTICS POOL

Christopher Bernard **CURETIS APPOINTS CEO OF NEWLY FORMED U.S. SUBSIDIARY**

Curetis, a developer of next-level molecular diagnostic solutions, has named Christopher Bernard to the newly created role of president and CEO of the company's North American subsidiary Curetis USA. He is

responsible for the development of the new subsidiary based in San Diego. Before joining Curetis, Mr. Bernard served as chief commercial officer of Epic Sciences.

▶ SERVICE POOL

Patrick Glaser **PATHEON NAMES SENIOR VP FOR SMALL MOLECULE API BUSINESS**

Patheon, a global provider of pharmaceutical development and manufacturing services, has appointed Patrick Glaser senior VP of the company's small molecule active pharmaceutical ingredient (API) business. He is responsible for leading the transformation and expansion of the company's API service offering in Europe and North America.

Mr. Glaser joins Patheon from Teva Pharmaceutical Industries where he served as VP of sales and marketing, API, North America.

▶ AGENCY POOL

Cliff Echols **Kerry Hutchings** **Cherie Squires** **SCORR MARKETING APPOINTS THREE**

INDUSTRY VETERANS TO SENIOR POSITIONS

SCORR Marketing, a global health science marketing and communications firm, has announced the addition of three employees, including Cliff Echols as market intelligence director and Kerry Hutchings and Cherie Squires as senior directors of program management.

As the market intelligence team leader, Mr. Echols helps clients access client satisfaction and lost opportunities, evaluates their market segmentation, measures brand awareness, appraises market perception and conducts competitor analysis to effectively develop marketing strategy. Before joining SCORR, he served as a research director at Bluebox Research.

As senior directors of program management, both Ms. Hutchings and Ms. Squires capitalize on their extensive health science industry experience to provide strategic direction to SCORR's global clients to meet their marketing goals. They develop marketing and communications programs and drive strategy and tactical solutions to ensure maximum visibility and to generate qualified leads.

Ms. Hutchings worked as the senior director of global strategic marketing at Worldwide Clinical Trials. Previously, Ms. Squires was the associate director of marketing at inVentiv Health Clinical. **PV**

TARGET PHARMAVOICE READERS WITH E-MAIL MARKETING

Searching for the right audience for your next e-mail campaign?

- Segment our opt-in e-mail database of 100,000
- Best practices for better ROI
- Design and html coding available
- 20% off multiple emails
- 50% off all resends

Pharma
VOICE

Reach your target audience selected by title, demographic, and industry type.



Call 215-321-8656 or e-mail mwalsh@pharmavoices.com to discuss your next e-mail promotion.